Amgen News Headlines (NASDAQ:AMGN)

$196.94
+1.29 (+0.66 %)
(As of 09/22/2019 02:08 PM ET)
Today's Range
$195.75
Now: $196.94
$199.32
50-Day Range
$182.16
MA: $199.24
$208.62
52-Week Range
$166.30
Now: $196.94
$211.90
Volume3.07 million shs
Average Volume2.71 million shs
Market Capitalization$118.10 billion
P/E Ratio13.68
Dividend Yield2.96%
Beta1.11

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
Amgen Looks Attractive After Its Recent Pullback - TheStreet.comAmgen Looks Attractive After Its Recent Pullback - TheStreet.com
www.thestreet.com - September 21 at 12:24 PM
Amgen Looks Attractive After Its Recent PullbackAmgen Looks Attractive After Its Recent Pullback
finance.yahoo.com - September 21 at 12:24 PM
Amgen (AMGN) Gains As Market Dips: What You Should KnowAmgen (AMGN) Gains As Market Dips: What You Should Know
finance.yahoo.com - September 20 at 9:32 PM
Bull of the Day: Amgen (AMGN) - Yahoo FinanceBull of the Day: Amgen (AMGN) - Yahoo Finance
finance.yahoo.com - September 20 at 11:29 AM
Amgen, Walt Disney, Microsoft, Apple and Oracle highlighted as Zacks Bull and Bear of the DayAmgen, Walt Disney, Microsoft, Apple and Oracle highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - September 20 at 11:29 AM
Read This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E Ratio - Yahoo FinanceRead This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E Ratio - Yahoo Finance
finance.yahoo.com - September 19 at 8:41 AM
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
finance.yahoo.com - September 19 at 8:41 AM
Read This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E RatioRead This Before You Buy Amgen Inc. (NASDAQ:AMGN) Because Of Its P/E Ratio
finance.yahoo.com - September 19 at 8:41 AM
Amgen Inc. (AMGN) Management Presents at The Bank of America Merrill Lynch Global Healthcare Conference (Transcript) - Seeking AlphaAmgen Inc. (AMGN) Management Presents at The Bank of America Merrill Lynch Global Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 18 at 2:02 PM
Verantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen - Yahoo FinanceVerantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen - Yahoo Finance
finance.yahoo.com - September 18 at 2:02 PM
Verantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen - PRNewswireVerantos Announces Publication of a Real-World Evidence Collaborative Study with Amgen - PRNewswire
www.prnewswire.com - September 18 at 9:01 AM
Could Amgens Latest Bad News Boost the Chances of More Acquisitions? - Motley FoolCould Amgen's Latest Bad News Boost the Chances of More Acquisitions? - Motley Fool
www.fool.com - September 18 at 9:01 AM
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 - PRNewswireAmgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 - PRNewswire
www.prnewswire.com - September 17 at 7:38 PM
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
finance.yahoo.com - September 17 at 7:38 PM
Amgen Inc. (AMGN?LTR=1)Amgen Inc. (AMGN?LTR=1)
finance.yahoo.com - September 17 at 10:35 AM
Adaptive Bio inks deal for clonoSEQ Assay with AmgenAdaptive Bio inks deal for clonoSEQ Assay with Amgen
seekingalpha.com - September 17 at 10:35 AM
Alder (ALDR) Stock Up on Acquisition Agreement With LundbeckAlder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
finance.yahoo.com - September 17 at 10:34 AM
Top Stock Picks for Week of September 16, 2019Top Stock Picks for Week of September 16, 2019
finance.yahoo.com - September 17 at 1:31 AM
Aimmune's Peanut Allergy Drug Gets FDA Committee's SupportAimmune's Peanut Allergy Drug Gets FDA Committee's Support
finance.yahoo.com - September 16 at 3:39 PM
Amgens Kyprolis Combo Improves PFS in Multiple Myeloma StudyAmgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
finance.yahoo.com - September 16 at 11:37 AM
Amgen $AMGN Trading ReportAmgen $AMGN Trading Report
www.marketwatch.com - September 16 at 11:37 AM
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levelsS&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
finance.yahoo.com - September 16 at 11:37 AM
Amgen (NASDAQ:AMGN) Receives Hold Rating from Leerink SwannAmgen (NASDAQ:AMGN) Receives Hold Rating from Leerink Swann
www.americanbankingnews.com - September 15 at 10:57 PM
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival - PRNewswireAmgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival - PRNewswire
www.prnewswire.com - September 14 at 11:09 AM
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference - PRNewswireAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference - PRNewswire
www.prnewswire.com - September 14 at 11:09 AM
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare ConferenceAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
finance.yahoo.com - September 14 at 11:09 AM
Amgen Is On The Right Track With Its Own Biosimilar To Rituxan - Seeking AlphaAmgen Is On The Right Track With Its Own Biosimilar To Rituxan - Seeking Alpha
seekingalpha.com - September 13 at 12:54 PM
2019 BusinessWoman of the Year honoree: Jaclyn Schuler2019 BusinessWoman of the Year honoree: Jaclyn Schuler
finance.yahoo.com - September 13 at 12:54 PM
Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?
finance.yahoo.com - September 13 at 12:54 PM
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
finance.yahoo.com - September 13 at 12:54 PM
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free SurvivalAmgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
finance.yahoo.com - September 13 at 12:54 PM
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKessonThe Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
finance.yahoo.com - September 13 at 12:54 PM
Celgene's (CELG) Leukemia Candidate Meets Endpoints in StudyCelgene's (CELG) Leukemia Candidate Meets Endpoints in Study
finance.yahoo.com - September 13 at 12:54 PM
Vertex Gains Reimbursement for Orkambi & Symkevi in ScotlandVertex Gains Reimbursement for Orkambi & Symkevi in Scotland
finance.yahoo.com - September 13 at 12:54 PM
Amgen Is On The Right Track With Its Own Biosimilar To RituxanAmgen Is On The Right Track With Its Own Biosimilar To Rituxan
seekingalpha.com - September 13 at 9:53 AM
Amgen slips on clinical hold on early-stage studies of MCL-1 inhibitors - Seeking AlphaAmgen slips on clinical hold on early-stage studies of MCL-1 inhibitors - Seeking Alpha
seekingalpha.com - September 12 at 7:19 PM
Top Research Reports for Amgen, Cisco & Berkshire Hathaway - Yahoo FinanceTop Research Reports for Amgen, Cisco & Berkshire Hathaway - Yahoo Finance
finance.yahoo.com - September 12 at 7:19 PM
Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 - PRNewswireAmgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 - PRNewswire
www.prnewswire.com - September 12 at 2:11 PM
Why Amgen Stock Perked Up Last Month - Motley FoolWhy Amgen Stock Perked Up Last Month - Motley Fool
www.fool.com - September 12 at 2:11 PM
5 Things Youll Want to Know About Amgens Future - Motley Fool5 Things You'll Want to Know About Amgen's Future - Motley Fool
www.fool.com - September 12 at 2:11 PM
BMO Capital Markets Reiterates "Buy" Rating for Amgen (NASDAQ:AMGN)BMO Capital Markets Reiterates "Buy" Rating for Amgen (NASDAQ:AMGN)
www.americanbankingnews.com - September 11 at 9:51 PM
Amgen (NASDAQ:AMGN) Given a $240.00 Price Target by Oppenheimer AnalystsAmgen (NASDAQ:AMGN) Given a $240.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - September 11 at 9:51 PM
Why Amgen Stock Perked Up Last MonthWhy Amgen Stock Perked Up Last Month
www.fool.com - September 11 at 11:43 AM
5 Things Youll Want to Know About Amgens Future5 Things You'll Want to Know About Amgen's Future
www.fool.com - September 11 at 8:24 AM
Amgens KRAS Inhibitor Shows Response in Larger NSCLC Group - NasdaqAmgen's KRAS Inhibitor Shows Response in Larger NSCLC Group - Nasdaq
www.nasdaq.com - September 11 at 6:12 AM
Amgen: Why This Cash Flow King Is A Buy - Seeking AlphaAmgen: Why This Cash Flow King Is A Buy - Seeking Alpha
seekingalpha.com - September 11 at 6:12 AM
Amgen Falls 3% - Yahoo FinanceAmgen Falls 3% - Yahoo Finance
finance.yahoo.com - September 11 at 6:12 AM
Amgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts - TheStreet.comAmgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts - TheStreet.com
www.thestreet.com - September 11 at 6:12 AM
Amgen: Otezla Brings Growth At A Reasonable Price - Seeking AlphaAmgen: Otezla Brings Growth At A Reasonable Price - Seeking Alpha
seekingalpha.com - September 11 at 6:12 AM
Is Nancy Pelosi's Drug-Pricing Plan Feasible — Or Is It A Political Ploy?Is Nancy Pelosi's Drug-Pricing Plan Feasible — Or Is It A Political Ploy?
finance.yahoo.com - September 11 at 6:12 AM
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel